Recombinant activated factor VII combined with local measures in preventing bleeding from invasive dental procedures in patients with Glanzmann thrombasthenia

Chuansumrit, Ampaiwan; Suwannuraks, M; Sri-Udomporn, Nantana; Pongtanakul, Bunchoo; Worapongpaiboon, Surapon

doi:10.1097/00001721-200302000-00011

Cited by 42 publications

(22 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A literature review revealed equal or less dosing of rFVIIa in comparison to our patient [3,4,7,9,[11][12][13]. The frequency of dosing intervals and the total duration of treatment should be individually adjusted, depending on the type of surgery and according to patient's clinical situation.…”

Section: Discussionmentioning

confidence: 99%

Perioperative haemostatic management of Glanzmann thrombasthenia for abdominal surgery

Lison¹,

Spannagl

Heindl³

2009

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

Glanzmann thrombasthenia is a rare congenital platelet disorder characterized by spontaneous mucocutaneous bleeding and severe bleeding complications during major surgery. This report centres on the perioperative haemostatic management of a patient with Glanzmann thrombasthenia undergoing elective major abdominal surgery. The treatment regimen was based mainly on recombinant activated factor VII, fibrinogen, and factor XIII, reducing platelet transfusion to a minimum. No red blood cell transfusions were needed perioperatively. For haemostatic monitoring, routine laboratory tests were sufficient.

show abstract

Section: Discussionmentioning

confidence: 99%

Perioperative haemostatic management of Glanzmann thrombasthenia for abdominal surgery

Lison¹,

Spannagl

Heindl³

2009

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

show abstract

“…Recombinant FVIIa has been shown to be effective in GT patients who are experiencing significant bleeding and who have either failed platelet transfusions, have platelet antibodies, or where it has been used to prevent platelet alloimmunization, and blood‐borne pathogen transmission. Many case reports have substantiated this success [69–74]. These are summarized in Table 2.…”

Section: Recombinant Fviia In Non‐haemophilia Bleeding In Childrenmentioning

confidence: 99%

Recombinant factor VIIa in paediatric bleeding disorders – a 2006 review

Mathew

Young

2006

Haemophilia

View full text Add to dashboard Cite

Recombinant factor VIIa (rFVIIa) has been used in haemophilia bleeding since its introduction in 1996. It has been found to be safe and effective in the majority of patients with haemophilia who have developed inhibitors. There is increasing use of rFVIIa in many off-label bleeding conditions, but there is a paucity of randomized studies regarding the use of rFVIIa in children. This review will attempt to address and summarize the studies focusing on the role of rFVIIa in both haemophilia and non-haemophilia bleeding conditions in children. rFVIIa has been administered as both bolus and continuous infusions, and at varying doses. Furthermore, adverse events have not reportedly increased in children despite growing experience with its use in the paediatric population.

show abstract

“…For mild-to-moderate bleeding in GT, the following approach is generally practiced: i) Local pressure/use of fibrin glue/human thrombin or use of other products such as collagen matrix may be effective in cases of mild bleeding [19,20]. Gelatin sponges soaked with antifibrinolytics such as epsilon aminocaproic acid (EACA) or tranexamic acid is often used locally to stop superficial bleeding.…”

Section: Local Measuresmentioning

confidence: 99%